Prevalence of Antimicrobial Resistance in Tanzania: A Systematic Review and Meta-Analysis

Charles Basil Kafaiya[1*], Johnson Mshiu[1], Obadia Bishoge[1,2], Jonathan Mcharo[1], Sia Malekia[1], Irene Mremi[1], Angelina M. Lutambi[1], Mwanaada Kilima[3], Mary Mayige[1], Said Aboud[1,4]

Authors Affiliations

[1]National Institute for Medical Research (NIMR), Dar es Salaam, Tanzania

[2]Department of Environmental and Occupational Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania

[3]Muhimbili National Hospital, Dar es Salaam, Tanzania

[4]Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania

[*]Corresponding author

E-mail: charles.kafaiya@nimr.or.tz (CBK)

Abstract

Antimicrobial resistance threatens global health. Understanding the resistance patterns aids treatment and promotes responsible antimicrobial use. This review and meta-analysis assess the prevalence of antimicrobial resistance among clinically relevant pathogens in Tanzania. A total of 18,265 studies identified from Google Scholar (18,000), PubMed (13), and Science Direct

(252), underwent screening and full article review. Ultimately, 28 studies were included. A subgroup analysis evaluated resistance patterns within antibiotic classes for specific pathogens. Descriptive statistics was used to describe the characteristics of the studies and the prevalence of antibiotic resistance. Heterogeneity was assessed using forest plots and the I^2 statistic. Among the included studies, the majority of the isolates (25.0%) were obtained from urine samples. Of these studies, 75% were cross-sectional studies, and 92.9% were conducted in hospital settings. The analysis revealed high resistance to penicillin, particularly amoxicillin-clavulanic and ampicillin, with Klebsiella pneumoniae (0.96 [0.83–0.99]), Acinetobacter baumannii (0.94 [0.67–0.99]) and Escherichia coli (0.90 [0.81–0.95]). Similarly, erythromycin resistance was most prevalent in Campylobacter spp. (0.85 [0.80–0.89]). Ciprofloxacin resistance was highest in Acinetobacter baumannii (0.54 [0.33–0.73]), while amikacin resistance with Proteus spp. was (0.86 [0.35–0.99]). Ceftriaxone resistance was particularly high in Acinetobacter baumannii (0.91 [0.70–0.98]) and Pseudomonas aeruginosa (0.85 [0.74–0.92]). Resistance to meropenem was lowest among Escherichia coli (0.04 [0.01–0.10]) and Klebsiella spp. (0.07 [0.03–0.15]), with an overall pooled resistance to the ESKAPE-E pathogen of (0.11[0.06–0.19]). Imipenem and clindamycin each had an overall pooled resistance of (0.06[0.02-0.14]) against both Escherichia coli and Klebsiella pneumoniae. The findings highlight widespread resistance among key bacterial pathogens - ESKAPE-E, particularly to *Access* and *Watch* groups of antibiotics. The variability in resistance patterns underscore the need to re-evaluate empirical treatment protocols (STG/NEMLIT) to ensure effective treatment regimens, strengthening antimicrobial stewardship, enhancing surveillance systems, and promote rational antibiotic use.

Keywords: Antimicrobial resistance, ESKAPE-E, AWaRe, Tanzania

Introduction

Antimicrobial resistance is when pathogens resist exposure to antibiotics meant to kill or slow their growth (1,2). It has become one of the leading public health threats of the 21st century, posing significant dangers to global health, economic stability, and the effectiveness of healthcare systems (3). The World Health Organization (WHO) has recognized antimicrobial resistance as a serious public health concern that can result in prolonged hospital admissions, greater medical expenses, and increased mortality rates (4). Furthermore, in 2017, the WHO identified ESKAPE pathogens; *Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,* and *Enterobacter* species as major global health threat due to their rising antibiotic resistance and potential to cause serious infections to human (2). This has made standard treatments become less effective as bacterial pathogens change, making it more difficult to treat once-treatable infections. This phenomenon is particularly noticeable in low- and middle-income countries, where antibiotic abuse is pervasive, infectious disease burdens are high, yet scarce healthcare resources (5–7).

In Tanzania, the prevalence of antibiotic resistance has been increasingly documented, yet comprehensive data remains sparse (8,9). A variety of factors contribute to the rising rates of Antimicrobial Resistance (AMR) in the country, including over-prescription of antibiotics, self-medication, and inadequate regulatory frameworks for antibiotic use. Additionally, socio-economic factors such as personal awareness, attitudes, practices, poverty, lack of access to healthcare services, and poor sanitation and hygiene practices exacerbate the situation (10). The interplay of these factors creates an environment conducive to the emergence and spread of resistant strains of bacteria.

Despite the urgency of the resistance pathogens, systematic reviews focusing specifically on Tanzania's antibiotic resistance landscape are limited. While several studies have reported resistance patterns for specific pathogens, therefore a consolidated analysis that captures the overall prevalence across the country was needed. This gap in knowledge hampers effective policy-making and public health interventions aimed at curbing antibiotic misuse and managing resistance. By combining available data, this systematic review and meta-analysis seeks to present a thorough overview of the prevalence of antibiotic resistance in Tanzania. A rigorous analysis of the published studies, was conducted to identify the prevalence of resistance pathogens among different antibiotics. This review will inform the National Action Plan on Antimicrobial Resistance 2023 -2028 to strengthen surveillance, infection control, and antibiotic resistance stewardship programs in the country.

Methodology

Protocol registration

The systematic review and meta-analysis protocol was registered through PROSPERO with an ID number PROSPERO 2024 CRD42024608537.

Settings

The evaluation was based on studies conducted in Tanzania; an East African country located in the African Great Lakes Region. It is bordered by Uganda to the northwest, Kenya to the northeast, the Indian Ocean to the east, Mozambique and Malawi to the south, Zambia to the southwest, and Rwanda, Burundi, and the Democratic Republic of the Congo to the west.

According to the 2022 national census, Tanzania has a population of approximately 62 million (11), making it the most populous country located wholly south of the equator. Antimicrobial resistance is a major public health issue in Tanzania, with a high prevalence of multidrug-resistant microorganisms (12). In clinical settings, the prevalence of multidrug-resistant bacteria varies between 25% and 50% (13). Previous research has shown a significant prevalence of methicillin-resistant *S. aureus* and extended-spectrum beta-lactamase-producing bacteria (14). Antimicrobial resistance risk factors in Tanzania include irrational antibiotic usage, inadequate hygiene and sanitation, transmission, sociodemographic characteristics, patient clinical information, and admission to healthcare facilities (15,16).

Review procedures

The systematic review began by identifying the research question and finalized with a report (17). The review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines for reviewing, analysing, and reporting systematic reviews (18), which covers all aspects of the manuscript, including the title, abstract, introduction, methods, results and discussion.

Search strategy

Relevant published studies were searched utilizing electronic databases such as PubMed, Science Direct, and Google Scholar. The following phrases were used in the search: ((("Prevalence"[Mesh] OR "Prevalences" OR "Point Prevalence" OR "Point Prevalences" OR "Prevalence, Point" OR "Period Prevalence" OR "Period Prevalences" OR "Prevalence, Period")

AND ("Risk Factors"[Mesh] OR "Factor, Risk" OR "Risk Factor" OR "Population at Risk" OR "Populations at Risk" OR "Risk Scores" OR "Risk Score" OR "Score, Risk" OR "Risk Factor Scores" OR "Risk Factor Score" OR "Score, Risk Factor" OR "Health Correlates" OR "Correlates, Health" OR "Social Risk Factors" OR "Factors, Social Risk" OR "Risk Factor, Social" OR "Risk Factors, Social" OR "Social Risk Factor")) AND ("Drug Resistance, Bacterial"[Mesh]OR "Antibacterial Drug Resistance" OR "Antibiotic Resistance, Bacterial")) AND ("Tanzania"[Mesh] OR "United Republic of Tanzania" OR "Zanzibar").

Selection criteria and search outcomes

The following criteria were used to select relevant studies: (i) studies reporting on the prevalence of antibiotic resistance in bacterial pathogens (ii) studies conducted in Tanzania over ten years, starting from 2014 to 2024, (iii) original cross-sectional studies, cohort studies, case-control studies, experimental studies or modelling studies and (iv) studies focused on antibiotic resistance. The review excluded studies not focusing on antibiotic resistance, animal or laboratory-based studies without clinical relevance, reviews, letters, notes, editorials and conference reports. The process yielded a total of 18,265 articles related to the study topic. Studies were uploaded to Covidence, a web-based software (19) for screening, full article review and data extraction. A total of 28 studies satisfied the set criteria and were thus included in this review (**Fig 1**).



Fig 1. Prisma flow chart of the systematic review and article selection.

Quality assessment

The included studies were evaluated for methodological quality and risk of bias using the Joanna Briggs Institute's Quality Assessment Tool for Cross-Sectional Studies (20,21). Studies were given a score of Yes, No, Unclear, and Not applicable (**S1 Table**).

S1 Table: **Quality Assessment Table.**

Data synthesis, analysis and reporting

The data was independently extracted by two researchers, focusing on various characteristics of the studies involved. These characteristics included the author and year of publication, study area, study design, study population, sampling methods, sample size, isolate samples, sources of samples, type of bacteria/pathogen, and type of antibiotic used. Descriptive statistics were used to summarize the characteristics of the studies using frequencies and percentages. A meta-analysis was performed to estimate pooled prevalence rates of antibiotic resistance, employing random-effects models. To evaluate heterogeneity among the studies, forest plots and I^2 statistic, were used, where higher values indicated significant heterogeneity (22). Subgroup analyses were conducted to investigate potential drug resistance to specific pathogens associated with each antibiotic. All analyses were conducted using the R libraries (meta) and (metafor) (23,24). Finally, the results were visually presented through tables and figures, including bar charts and forest plots.

Results

Study characteristics

Settings, study designs and year of publication of the selected studies

Out of the 28 included studies, the majority (32%) were conducted in Dar es Salaam, followed by Mwanza (25%) and Kilimanjaro (17.9%), with 75.0% being cross-sectional. Additionally, 17.9% of the studies were published in 2020, while 14.3% were published in 2016, 2019, and 2022 (**Fig 2**).



Fig 2. Distribution of Year of Publication, Study Design, and Region.

Study population, sample size and number of isolates

The majority of the selected studies (46%) involved children under five years. The sample size of the selected studies ranged from 75 (25) to 4,306 (26) with the number of isolates of 22 (27) to 4,030 (26) (**Table 1**). The most common clinical samples were urine (25%), nasopharyngeal swabs (10.7%), open wound pus swabs (7.1%) and blood (3.6%) (**Fig 3**).

Table 1: Study population, sampling methods, sample size, number of isolates and sample sources of the selected studies

Author	**Study population**	**Sample Size**	**Number of Isolates**
Manyahi et al., 2014 (28)	Patients with clinical evidence of SSI	100	147
Moyo et al., 2014 (29)	Healthy under-fives	114	114
Marwa et al., 2015 (30)	HIV/AIDS patients	945	155
Komba et al., 2015 (31)	Patients with enteric and non-enteric symptoms	1195	136
Ahmed et al., 2015 (32)	Malnourished under-fives	402	84
Okamo et al., 2016 (33)	Medical students	314	66
Moremi et al., 2016 (34)	More samples were from paediatric population	3330	439
Tellevik et al., 2016 (35)	Children Below 2 years	603	284
Seidman et al., 2016 (36)	Young children	377	2492
Ahmed et al., 2017 (37)	Malnourished under-fives	402	42
Joachim et al., 2017 (27)	Patients attended at EMD/IPD	258	22
Kumburu et al., 2017 (38)	Patient admitted in surgical and medical department	575	377
Kiponza et al., 2019 (39)	Post-delivery women	197	107
Seni et al., 2019 (40)	Pregnant women with significant bacteriuria	1828	323
Emgård et al., 2019 (41)	Children	775	244
Madut et al., 2019 (42)	Adolescent and adult patients aged ≥13 y with fever.	1648	31
Daud et al., 2020 (43)	Children	282	282
Kamgobea et al., 2020 (44)	Pregnant women with or without PROM	350	39
Mikomangwa et al., 2020 (45)	Patients attended	183	201
Manyahi et al., 2020 (46)	All inpatients with features suggestive of BSI	402	44

Kadigi et al., 2020 (47)	Under-fives with symptoms of UTI	270	80
Letara et al., 2021 (48)	Children	350	76
Sangeda et al., 2021 (49)	Under-fives with symptoms of UTI	214	35
Manyahi et al., 2022 (50)	Admitted patients	198	179
Masoud et al., 2022 (25)	Admitted patients	75	76
Schmider et al., 2022 (51)	Outpatients aged ≥2 years with symptoms of UTI	270	119
Silago et al., 2022 (52)	Patients who resided within the study area	1327	412
Muhiddin Hamada Omar 2024 (26)	Hospitalized patients	4306	4030



Fig 3. Sources of samples for the selected studies.

Results from meta-analysis

The meta-analysis included 28 studies investigating antibiotic resistance patterns across a broad spectrum of pathogens, including ESKAPE-E bacteria (*Escherichia coli*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter spp.*), *Proteus spp.*, *Streptococcus spp.*, *Campylobacter spp.*, and *P. mirabilis.*

The review examined various pathogens against 17 antibiotics, including penicillin (amoxicillin and ampicillin), macrolides (erythromycin), fluoroquinolones (ciprofloxacin), aminoglycosides (amikacin), tetracyclines (tetracycline), sulphonamides (trimethoprim-sulfamethoxazole), and cephalosporins (2nd,3rd and 4th generations). It also included carbapenems (meropenem, imipenem), lincosamides (clindamycin), and nitrofuran compounds (nitrofurantoin) (**S1-S14 Figs) (Fig. 4-6**).

A subgroup analysis was conducted to assess resistance patterns within each antibiotic class for specific pathogens. The results revealed high resistance to penicillin (*Amoxicillin - Clavulanic Acid*), with the highest pooled prevalence observed in *Acinetobacter baumannii* (0.92 [0.76–0.98]), followed by *Proteus mirabilis* (0.87 [0.63–0.96]), *Klebsiella pneumoniae* (0.85 [0.73–0.92]), and *Enterobacter spp.* (0.83 [0.61–0.94]). Resistance was also notable among *Escherichia coli* (0.61 [0.42–0.77]) and *Klebsiella spp.* (0.53 [0.20–0.84]) (**Fig 1**). Similarly, a high level of resistance to penicillin (ampicillin) was observed among ESKAPE-E pathogens as well as *Proteus* spp. The pooled prevalence of resistance ranged from *Klebsiella pneumoniae* (0.96 [0.83–0.99]), *Acinetobacter baumannii* (0.94 [0.67–0.99]), *Escherichia coli* (0.90 [0.81–0.95]), *Klebsiella* spp. (0.90 [0.81–0.95]), *Enterobacter cloacae* (0.78 [0.46–0.94]), *Pseudomonas aeruginosa* (0.77 [0.47–0.92]), *Proteus* spp. (0.76 [0.58–0.88]), and *Staphylococcus aureus* (0.76 [0.38–0.94]) (**S1 Fig**).



Fig 4. Amoxicillin/clavulanic acid resistance patterns among various pathogens.

Resistance to macrolides, specifically erythromycin, was highest in *Campylobacter spp.* (0.85 [0.80–0.89]), followed by *Escherichia coli* (0.61 [0.16–0.93]) and *Staphylococcus aureus* (0.52 [0.35–0.68]) (**S2 Fig**). Ciprofloxacin exhibited a pooled resistance prevalence of 0.54 [0.33–0.73] in *Acinetobacter baumannii* (**S3 Fig**), while amikacin resistance was notably high in *Proteus spp.* (0.86 [0.35–0.99]) (**S4 Fig**). Tetracycline resistance was prevalent in *Klebsiella pneumoniae* (0.81 [0.24–0.98]) and *Escherichia coli* (0.77 [0.71–0.83]) (**S5 Fig**). Additionally, trimethoprim-sulfamethoxazole showed high resistance in *Klebsiella pneumoniae* (0.93 [0.77–0.98]), *Escherichia coli* (0.86 [0.75–0.93]), and *Proteus mirabilis* (0.80 [0.30–0.97]) (**S6 Fig**).

The pathogens exhibiting the highest resistance to ceftriaxone, a third-generation cephalosporin, include *Acinetobacter baumannii* (0.91 [0.70–0.98]), *Proteus mirabilis* (0.71 [0.47–0.87]), *Klebsiella species* (0.65 [0.40–0.84]), *Klebsiella pneumoniae* (0.74 [0.59–0.85]), and *Pseudomonas aeruginosa* (0.85 [0.74–0.92]) (**Fig 2**). Similarly, high resistance to cefotaxime was observed in *Acinetobacter baumannii* (0.92 [0.53–0.99]), *Pseudomonas aeruginosa* (0.90 [0.53–0.99]), *Klebsiella pneumoniae* (0.94 [0.62–0.99]), *Escherichia coli* (0.81 [0.35–0.97]), and *Proteus mirabilis* (0.81 [0.24–0.98]) (**S7 Fig**).



Fig 5. Ceftriaxone resistance patterns among various pathogens.

For ceftazidime, the highest resistance was noted among *Klebsiella pneumoniae* (0.89 [0.64–0.97]), *Acinetobacter baumannii* (0.82 [0.58–0.93]), and *Proteus mirabilis* (0.67 [0.44–0.84]) (**S8 Fig**). Resistance to the fourth-generation cephalosporin, cefepime, was also observed across multiple bacterial species, with *Enterobacter species* (0.91 [0.66–0.98]), *Escherichia coli* (0.86 [0.14–1.00]), *Klebsiella species* (0.73 [0.59–0.83]), and *Citrobacter species* (0.72 [0.47–0.88]) (**S9 Fig**).

Despite the overall high resistance observed among pathogens against specific antibiotics, certain pathogens exhibited lower pooled resistance prevalence. *Escherichia coli* and *Staphylococcus aureus* had resistance to cefuroxime of (0.38 [0.19–0.60]) and cefoxitin of (0.38 [0.26–0.53]), respectively (**S10**–**S11 Figs**). The ESKAPE-E pathogens were tested against meropenem, exhibiting an overall pooled resistance prevalence of (0.11 [0.06–0.19]). Among individual pathogens, *Escherichia coli* showed the lowest resistance at (0.04 [0.01–0.10]), followed by *Klebsiella species* at (0.07 [0.03–0.15]), *Enterobacter cloacae* at (0.07 [0.01–0.37]), *Pseudomonas aeruginosa* at 0.30 [0.18–0.46], and *Staphylococcus aureus* at (0.27 [0.07–0.66]) (**Fig 3**). Notably, *Acinetobacter baumannii* exhibited the highest resistance at 0.45 [0.27–0.65]. For imipenem, *Klebsiella pneumoniae* and *Escherichia coli* had an overall pooled resistance prevalence of 0.06 [0.02–0.26], with individual resistance rates of (0.08 [0.02–0.26]) and (0.06 [0.02–0.26]), respectively (**S12 Fig)**. Similarly, *Klebsiella pneumoniae* and *Escherichia coli* exhibited an overall pooled resistance prevalence of (0.06 [0.02–0.14]) to clindamycin (**S13 Fig**). In the case of nitrofurantoin, *Staphylococcus aureus*, *Escherichia coli*, and *Klebsiella species* demonstrated an overall pooled resistance prevalence of (0.24 [0.16–0.34]) (**S14 Fig**). The

included studies demonstrated moderate to substantial heterogeneity across pathogens and antibiotics, with 76.5% exhibiting high heterogeneity (above 75%).



Fig 6. Meropenem resistance patterns among various pathogens.

Discussion

The focus of this systematic review was to investigate the prevalence of antimicrobial resistance in Tanzania. The findings indicate alarmingly high resistance rates to *AWaRe (Access, Watch, Reserve)* classes of antibiotics in Tanzania. The ESKAPE-E pathogens have exhibited high resistance to a wide range of these groups of antibiotics, which suggests a significant challenge in treating infections caused by these pathogens in the country (53).

ESKAPE-E pathogens are the leading causes of urinary tract infections, surgical site infections, skin infections, upper and lower respiratory infections, bloodstream infections, and nosocomial infections in Tanzania (54,55)**.** The current study identified high resistance rates among these pathogens to commonly used *Access group* of antibiotics, including *nitrofurantoin (24%), erythromycin (56%), amoxicillin-clavulanic acid (66%), Tetracycline(67%), and ampicillin (86%).* A study conducted in South Africa and a review conducted in East Africa in 2005 to 2015 involving Uganda, Kenya, Ethiopia, Rwanda and The Democratic Republic of Congo have reported similar resistance patterns(56,57). These elevated resistance levels significantly compromise treatment efficacy, leading to prolonged illness, increased healthcare costs, and higher mortality rates (58,59).

Taking into consideration individual pathogens and specific *Access group* of antibiotics, the resistance to *ampicillin* was particularly alarming, with 96% of *Klebsiella pneumoniae*, 94% of *Acinetobacter baumannii*, and 90% of *Escherichia coli* isolates exhibiting resistance. Given that ampicillin is recommended as one of the treatment options for these pathogens in Tanzania Standard Treatment Guidelines (60), such high resistance raises concerns about treatment complications and prolonged hospital stays. These findings align with previous studies

conducted in South Africa and East African countries (61,62), further emphasizing the need for urgent interventions.

Moreover, *Acinetobacter baumannii*, *Proteus mirabilis*, and *Klebsiella pneumoniae* exhibited high resistance rates to *amoxicillin-clavulanic acid* at 92%, 87%, and 85%, respectively, complicating the effective management of bloodstream infections, wound infections, urinary tract infections (UTIs), Upper respiratory infections and pneumonia(63–66). Similar resistance patterns have been reported in previous studies(67), highlighting the growing challenge of antimicrobial resistance in these pathogens. However, nitrofurantoin, commonly recommended for UTIs treatment in Tanzania (60), showed relatively lower resistance rates, with *Escherichia coli* (21%), *S. aureus* (24%), and *Klebsiella spp.* (32%). These findings are in line with other studies (68), suggesting that nitrofurantoin remains a viable treatment option for UTIs, although continuous monitoring is essential.

Furthermore, more than half of the samples tested for *erythromycin* susceptibility exhibited resistance, with *Campylobacter spp.* (85%), *Escherichia coli* (61%), and *Staphylococcus aureus* (52%) showing notable resistance levels. This trend aligns with findings from studies conducted in Kenya (69) and a review conducted in Africa (70), reinforcing concerns regarding the declining effectiveness of erythromycin.

Similarly, *Watch group* of antibiotics have revealed an overall resistance for *sulphonamides(84%)*, *ceftriaxone*(60%), *ceftazidime(55%)*, *cefuroxime(38%)* and *ciprofloxacin(34%).* Ceftriaxone, a crucial antibiotic for severe blood stream infections, surgical site infections, complicated UTIs and gastrointestinal infections has shown higher resistance to a wide range of pathogens. With *A. baumannii* demonstrating a resistance of 91%, followed by *Pseudomonas aeruginosa* (85%) and *K. pneumoniae* (74%). These findings are consistent with a

review conducted focusing on *A. baumannii* in 2019 (71), which have reported similar high resistance levels, further emphasizing the limited efficacy of ceftriaxone in treating severe bacterial infections. Moreover, Ciprofloxacin resistance was assessed among ESKAPE-E pathogens, with more than half of the *A. baumannii* demonstrating resistance, while other pathogens exhibited resistance rates below than 50%. This high resistance in A. *baumannii* may indicate selective pressure due to the widespread use of ciprofloxacin, particularly in the management of urinary tract infections (UTIs), post-operative care, and bloodstream infections (72–74). Despite the observed resistance, ciprofloxacin remains effective for treating these infections. However, caution is needed to prevent further resistance development through prudent use and antimicrobial stewardship programs.

The *reserved group* of antibiotics, intended for last resort use, including *carbapenems*, *amikacin*, *clindamycin* and *cefepime* have revealed heterogenous resistance ranging from as low as 6% to as high as 81%. This trend raises concerns about treatment outcomes for complicated cases referred from lower-level facilities where *Access group* antibiotics have failed. When analysing resistance by specific antibiotic-pathogen combinations, both *clindamycin* and *imipenem* exhibited relatively low resistance rates against *E. coli* (8%) and *K. pneumoniae* (3%), respectively. The lower resistance observed for these antibiotics can be attributed to restricted access, as they are not available over the counter, thereby reducing misuse and selective pressure (75). These findings align with studies conducted in Uganda and South Africa(76,77), which have also reported lower resistance rates to these reserved antibiotics.

Among ESKAPE-E pathogens, *meropenem* demonstrated relatively low resistance, with *E. coli* (4%), *Klebsiella spp.* (7%), and *Enterobacter cloacae* (7%). However, *A. baumannii* showed notably higher resistance, which may reflect its well-documented ability to develop

multidrug resistance (71). These findings underscore the importance of maintaining strict control over the use of these *reserved* antibiotics while implementing continuous surveillance to prevent resistance escalation. Similar trends have been observed in studies conducted in South Africa and Ethiopia (76,78,79), further supporting the need for ongoing monitoring. Conversely, *cefepime* and *amikacin* exhibited significantly higher resistance rates, particularly in *E. coli* (86%, 20%, respectively). Alarmingly, elevated resistance was also observed in *Enterobacter spp.* (91%, *cefepime*) and *Proteus spp.* (86%, *amikacin*), suggesting that these previously reserved antibiotics may be losing their efficacy. These findings are similar to the studies conducted in Iran, USA, India and Africa (80–83), where higher resistance rates were reported, highlighting the potential regional differences in antibiotic use and resistance patterns.

This review provides valuable insights into the pooled prevalence of antimicrobial resistance in Tanzania. However, there are some limitations. The majority of the studies were conducted in hospital settings, which may limit the generalizability of the findings to the broader population. Similarly, over half of the studies were carried out in urban areas, particularly in Dar es Salaam and Mwanza.

Conclusion

The current review highlights the critical and troubling rates of antimicrobial resistance among *ESKAPE-E* pathogens in Tanzania, which create significant challenges in managing urinary tract infections (UTIs), Upper respiratory tract infections, skin infections, bloodstream infections, pneumonia, and wound infections effectively. The high resistance to *Access* and *Watch* groups of antibiotics indicates that standard treatment regimens may no longer be reliable, resulting in longer illnesses, increased healthcare expenses, and higher mortality rates. Although

resistance levels to reserved antibiotics like *carbapenems*, *cefepime* and *amikacin* are relatively low, troubling trends have been observed, especially with *A. baumannii*, *E. coli*, *Proteus spp* and *Enterobacter spp*. This situation emphasizes the need to protect these last-resort treatments through rigorous antimicrobial stewardship, regulatory policies and considering revising the Tanzania Standard Treatment Guidelines. Moreover, implementing prescription regulations is essential in combatting the ongoing development of antimicrobial resistance.

Abbreviations

ESKAPE-E (*Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter* spp, *Escherichia coli*), **STG** (Standard Treatment Guideline), **NEMLIT** (The National Essential Medicines List of Tanzania), **AMR** (Antimicrobial resistance), **BSI** (bloodstream infections), **SSI** (Surgical Site Infection), ***AWaRe*** (*Access, Watch, Reserve*), ***Access*** (Penicillin, Erythromycin, Tetracycline, Nitrofurantoin) ***Watch*** (Cephalosporins, Ciprofloxacin, Sulphonamides), ***Reserve*** (Carbapenems, Cefepime, Clindamycin, Amikacin).

Acknowledgement

The authors would like to thank the researchers who published their articles online, without which this review would not have been possible.

Authors contribution

CBK, OB and JM (conceptualization, protocol registration, literature search, full article review, writing the manuscript), JJM (conceptualization, data analysis and interpretation), SM and IM (Screening and data extraction), AML (Screening, data extraction and review) and MK, MM and SA (review of the manuscript)

Funding statement

No funding received for this review

Data availability

The datasets used in this review are available upon request to the corresponding author. All relevant data are given separately as a supplementary file.

Competing interests

None declared.

References

1. NFID. Antibiotic Resistance - NFID [Internet]. 2024 [cited 2025 Mar 7]. Available from: https://www.nfid.org/antibiotic-resistance/
2. Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial antibiotic resistance: the most critical pathogens. Pathogens [Internet]. 2021 Oct 1 [cited 2025 Mar 7];10(10):1310. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8541462/
3. Murray CJL, Ikuta KS, Sharara F. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022 Feb;399(10325):629–55.
4. WHO. Antimicrobial resistance [Internet]. 2023 [cited 2025 Mar 5]. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
5. Iskandar K, Molinier L, Hallit S, Sartelli M, Catena F, Coccolini F, et al. Drivers of Antibiotic Resistance Transmissionin Low- and Middle-Income Countriesfrom a "One Health" Perspective-A Review. Antibiotics (Basel). 2020 Jul;9(7).
6. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022 Feb 12;399(10325):629–55.
7. WHO. Antimicrobial resistance [Internet]. 2023 [cited 2025 Mar 7]. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
8. Camara N, Moremi N, Mghamba J, Eliakimu E, Shumba E, Ondoa P, et al. Surveillance of antimicrobial resistance in human health in Tanzania: 2016-2021. Afr J Lab Med. 2023;12(1):2053.
9. Katyali D, Kawau G, Blomberg B, Manyahi J. Antibiotic use at a tertiary hospital in Tanzania: findings from a point prevalence survey. Antimicrob Resist Infect Control. 2023;12(1):112.
10. Sindato C, Mboera LEG, Katale BZ, Frumence G, Kimera S, Clark TG, et al. Knowledge, attitudes and practices regarding antimicrobial use and resistance among communities of Ilala, Kilosa and Kibaha districts of Tanzania. Antimicrob Resist Infect Control. 2020;9:1–17.
11. URT. The 2022 Population and House Census. Initial results. 2022.
12. Silago V, Oravcova K, Matthews L, Mshana SE, Claus H, Seni J. Epidemiology and antimicrobial resistance trends of pathogens causing urinary tract infections in Mwanza, Tanzania: A comparative study during and after the implementation of the National Action Plan on Antimicrobial Resistance (2017-2022). International Journal of Infectious Diseases. 2024;147:107208.
13. Frumence G, Mboera LEG, Katale BZ, Sindato C, Kimera S, Durrance-Bagale A, et al. Policy actors and human and animal health practitioners' perceptions of antimicrobial use and resistance in Tanzania: A qualitative study. J Glob Antimicrob Resist. 2021 Jun;25:40–7.
14. Katyali D, Kawau G, Blomberg B, Manyahi J. Antibiotic use at a tertiary hospital in Tanzania: findings from a point prevalence survey. Antimicrob Resist Infect Control [Internet]. 2023 Dec 1 [cited 2025 Mar 7];12(1):1–7. Available from: https://aricjournal.biomedcentral.com/articles/10.1186/s13756-023-01317-w

15. Emgård M, Mwangi R, Mayo C, Mshana E, Nkini G, Andersson R, et al. Tanzanian primary healthcare workers' experiences of antibiotic prescription and understanding of antibiotic resistance in common childhood infections: a qualitative phenomenographic study. Antimicrob Resist Infect Control. 2021;10:1–15.
16. Mkinga DA, Lyamuya FS. Aetiology and Antimicrobial Susceptibility Pattern of Bacteria Pathogens from Hospitalised Adult Patients at a Tertiary Care Hospital in North Eastern Tanzania. East Africa Science. 2022 Mar 31;4(1):54–61.
17. Tawfik GM, Dila KAS, Mohamed MYF, Tam DNH, Kien ND, Ahmed AM, et al. A step by step guide for conducting a systematic review and meta-analysis with simulation data. Trop Med Health. 2019;47(1):46.
18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. The BMJ. 2021;372:1–9.
19. Covidence. Covidence - Better systematic review management [Internet]. 2025 [cited 2025 Mar 27]. Available from: https://www.covidence.org/
20. JBI. Checklist for Analytical Cross Sectional Studies Critical Appraisal Checklist for Analytical Cross Sectional Studies 2. 2017 [cited 2025 Mar 14]; Available from: http://joannabriggs.org/research/critical-appraisal-tools.htmlwww.joannabriggs.org
21. Barker TH, Stone JC, Sears K, Klugar M, Leonardi-Bee J, Tufanaru C, et al. Revising the JBI quantitative critical appraisal tools to improve their applicability: an overview of methods and the development process. JBI Evid Synth [Internet]. 2023 Nov 22 [cited 2025 Mar 14];21(3):478–93. Available from: https://journals.lww.com/jbisrir/fulltext/2023/03000/revising_the_jbi_quantitative_critical_appraisal.4.aspx
22. Dettori JR, Norvell DC, Chapman JR. Seeing the Forest by Looking at the Trees: How to Interpret a Meta-Analysis Forest Plot. Global Spine J. 2021 May 3;11(4):614–6.
23. Viechtbauer W. Conducting Meta-Analyses in *R* with the **metafor** Package. J Stat Softw. 2010;36(3).
24. Schwarzer G, Carpenter JR, Rücker G. Meta-Analysis with R. Cham: Springer International Publishing; 2015.
25. Masoud SS, Kovacevich A, Gangji R, Nyawale H, Nyange M, Ntukula A. Extent and resistance patterns of ESKAPE pathogens isolated in pus swabs from hospitalized patients. Canadian Journal of Infectious Diseases and Medical Microbiology. 2022;2022(1):3511306.
26. Omar MH, Kilale AM, Rashid HK, Mwakapeje ER, Onoka IM, Gimbi AA. Prevalence and risk factors for extended-spectrum β-lactamase producing antimicrobial-resistant E. coli in urinary tract infections among inpatients in the tertiary hospitals in Zanzibar (Tanzania): a prospective cross-sectional study. Pan Afr Med J. 2024;47:193.
27. Joachim A, Moyo SJ, Nkinda L, Majigo M, Mmbaga E, Mbembati N, et al. Prevalence of methicillin-resistant Staphylococcus aureus carriage on admission among patients attending regional hospitals in Dar es Salaam, Tanzania. BMC Res Notes. 2017 Aug;10(1):417.

469 28. Manyahi J, Matee MI, Majigo M, Moyo S, Mshana SE, Lyamuya EF. Predominance of
470 multi-drug resistant bacterial pathogens causing surgical site infections in Muhimbili
471 National Hospital, Tanzania. BMC Res Notes. 2014;7:1–7.
472 29. Moyo SJ, Aboud S, Blomberg B, Mkopi N, Kasubi M, Manji K, et al. High nasal carriage of
473 methicillin-resistant Staphylococcus aureus among healthy Tanzanian under-5 children.
474 Microbial Drug Resistance. 2014;20(1):82–8.
475 30. Marwa KJ, Mushi MF, Konje E, Alele PE, Kidola J, Mirambo MM. Resistance to
476 Cotrimoxazole and Other Antimicrobials among Isolates from HIV/AIDS and Non-HIV/AIDS
477 Patients at Bugando Medical Centre, Mwanza, Tanzania. AIDS Res Treat.
478 2015;2015(1):103874.
479 31. Komba EVG, Mdegela RH, Msoffe PLM, Nielsen LN, Ingmer H. Prevalence, Antimicrobial
480 Resistance and Risk Factors for Thermophilic Campylobacter Infections in Symptomatic
481 and Asymptomatic Humans in Tanzania. Zoonoses Public Health. 2015 Nov;62(7):557–68.
482 32. Ahmed M, Moremi N, Mirambo MM, Hokororo A, Mushi MF, Seni J, et al. Multi-resistant
483 gram negative enteric bacteria causing urinary tract infection among malnourished
484 underfives admitted at a tertiary hospital, northwestern, Tanzania. Ital J Pediatr.
485 2015;41:1–5.
486 33. Okamo B, Moremi N, Seni J, Mirambo MM, Kidenya BR, Mshana SE. Prevalence and
487 antimicrobial susceptibility profiles of Staphylococcus aureus nasal carriage among pre-
488 clinical and clinical medical students in a Tanzanian University. BMC Res Notes. 2016
489 Jan;9:47.
490 34. Moremi N, Claus H, Mshana SE. Antimicrobial resistance pattern: a report of
491 microbiological cultures at a tertiary hospital in Tanzania. BMC Infect Dis. 2016;16(1):756.
492 35. Tellevik MG, Blomberg B, Kommedal Ø, Maselle SY, Langeland N, Moyo SJ. High
493 Prevalence of Faecal Carriage of ESBL-Producing Enterobacteriaceae among Children in
494 Dar es Salaam, Tanzania. PLoS One. 2016;11(12):e0168024.
495 36. Seidman JC, Johnson LB, Levens J, Mkocha H, Muñoz B, Silbergeld EK, et al. Longitudinal
496 comparison of antibiotic resistance in diarrheagenic and non-pathogenic Escherichia coli
497 from young Tanzanian children. Front Microbiol. 2016;7:1420.
498 37. Ahmed M, Mirambo MM, Mushi MF, Hokororo A, Mshana SE. Bacteremia caused by
499 multidrug-resistant bacteria among hospitalized malnourished children in Mwanza,
500 Tanzania: a cross sectional study. BMC Res Notes. 2017;10:1–5.
501 38. Kumburu HH, Sonda T, Mmbaga BT, Alifrangis M, Lund O, Kibiki G, et al. Patterns of
502 infections, aetiological agents and antimicrobial resistance at a tertiary care hospital in
503 northern Tanzania. Tropical Medicine & International Health. 2017;22(4):454–64.
504 39. Kiponza R, Balandya B, Majigo M V, Matee M. Laboratory confirmed puerperal sepsis in a
505 national referral hospital in Tanzania: etiological agents and their susceptibility to
506 commonly prescribed antibiotics. BMC Infect Dis. 2019;19:1–7.
507 40. Seni J, Tito JN, Makoye SJ, Mbena H, Alfred HS, van der Meer F, et al. Multicentre
508 evaluation of significant bacteriuria among pregnant women in the cascade of referral
509 healthcare system in North-western Tanzania: Bacterial pathogens, antimicrobial
510 resistance profiles and predictors. J Glob Antimicrob Resist. 2019 Jun;17(11):173–9.
511 41. Emgård M, Msuya SE, Nyombi BM, Mosha D, Gonzales-Siles L, Nordén R, et al. Carriage of
512 penicillin-non-susceptible pneumococci among children in northern Tanzania in the 13-

513 valent pneumococcal vaccine era. International Journal of Infectious Diseases.
514 2019;81:156–66.
515 42. Madut DB, Rubach MP, Kalengo N, Carugati M, Maze MJ, Morrissey AB, et al. A
516 prospective study of Escherichia coli bloodstream infection among adolescents and
517 adults in northern Tanzania. Trans R Soc Trop Med Hyg. 2020 May;114(5):378–84.
518 43. Daud M, Nyombi B. Antimicrobial Resistance Pattern in Escherichia coli Isolated from
519 Children Admitted at Selected Health Care Facilities in Moshi Municipality, Tanzania.
520 South Asian Journal of Research in Microbiology. 2020;6(3):33–9.
521 44. Kamgobe E, Grote S, Mushi MF, Wilson D, Gandye L, Bader O, et al. Multi-drug resistant
522 facultative pathogenic bacteria colonizing the vagina of pregnant women with premature
523 rupture of membrane, Tanzania. East Africa Science. 2020;2(1):29–35.
524 45. Mikomangwa WP, Bwire GM, Kilonzi M, Mlyuka H, Mutagonda RF, Kibanga W, et al. The
525 existence of high bacterial resistance to some reserved antibiotics in tertiary hospitals in
526 Tanzania: a call to revisit their use. Infect Drug Resist. 2020;1831–8.
527 46. Manyahi J, Kibwana U, Mgimba E, Majigo M. Multi-drug resistant bacteria predict
528 mortality in bloodstream infection in a tertiary setting in Tanzania. PLoS One.
529 2020;15(3):e0220424.
530 47. Kadigi D, Mosha F, Moyo S, Matee M. Etiology and antimicrobial susceptibility patterns of
531 bacterial agents causing urinary tract infection in children under five years, dar es salaam.
532 Journal of Biotechnology and Immunology. 2020;2(1):2.
533 48. Letara N, Ngocho JS, Karami N, Msuya SE, Nyombi B, Kassam NA, et al. Prevalence and
534 patient related factors associated with Extended-Spectrum Beta-Lactamase producing
535 Escherichia coli and Klebsiella pneumoniae carriage and infection among pediatric
536 patients in Tanzania. Sci Rep. 2021;11(1):22759.
537 49. Sangeda RZ, Paul F, Mtweve DM. Prevalence of urinary tract infections and antibiogram
538 of uropathogens isolated from children under five attending Bagamoyo District Hospital
539 in Tanzania: a cross-sectional study. F1000Res. 2021;10:449.
540 50. Manyahi J, Majigo M, Kibwana U, Kamori D, Lyamuya EF. Colonization of Extended-
541 spectrum β-lactamase producing Enterobacterales and meticillin-resistant S. aureus in
542 the intensive care unit at a tertiary hospital in Tanzania: Implications for Infection control
543 and prevention. Infection Prevention in Practice. 2022;4(2):100212.
544 51. Schmider J, Bühler N, Mkwatta H, Lechleiter A, Mlaganile T, Utzinger J, et al.
545 Microbiological characterisation of community-acquired urinary tract infections in
546 Bagamoyo, Tanzania: a prospective study. Trop Med Infect Dis. 2022;7(6):100.
547 52. Silago V, Moremi N, Mtebe M, Komba E, Masoud S, Mgaya FX, et al. Multidrug-resistant
548 uropathogens causing community acquired urinary tract infections among patients
549 attending health facilities in Mwanza and Dar es Salaam, Tanzania. Antibiotics.
550 2022;11(12):1718.
551 53. Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial antibiotic resistance: the most critical
552 pathogens. Pathogens [Internet]. 2021 Oct 1 [cited 2025 Mar 7];10(10):1310. Available
553 from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8541462/
554 54. Silago V, Oravcova K, Matthews L, Mshana SE, Claus H, Seni J. Epidemiology and
555 antimicrobial resistance trends of pathogens causing urinary tract infections in Mwanza,
556 Tanzania: A comparative study during and after the implementation of the National

557 Action Plan on Antimicrobial Resistance (2017-2022). International Journal of Infectious
558 Diseases [Internet]. 2024 Oct 1 [cited 2025 Mar 12];147:None. Available from:
559 https://pmc.ncbi.nlm.nih.gov/articles/PMC11442316/
560 55. Augustine FF, Mgaya FX, Yahya SA, Niccodem EM, Matee MI. German Journal of
561 Microbiology An alarming prevalence of multidrug-resistant (MDR) ESKAPE pathogens
562 and other drug-resistant bacteria isolated from patients with bloodstream infections
563 hospitalized at Muhimbili National Hospital in Dar es Salaam, Tanzania. [cited 2025 Mar
564 12]; Available from: https://doi.org/10.51585/gjm.2023.3.0026
565 56. Ampaire L, Muhindo A, Orikiriza P, Mwanga-Amumpaire J, Bebell L, Boum Y. A review of
566 antimicrobial resistance in East Africa. Vol. 5, African Journal of Laboratory Medicine.
567 AOSIS OpenJournals Publishing AOSIS (Pty) Ltd; 2016.
568 57. Mthombeni TC, Burger JR, Lubbe MS, Julyan M, Lekalakala-Mokaba MR, Mthombeni T.
569 African Journal of Laboratory Medicine. 2225;2002–225. Available from:
570 https://doi.org/10.4102/ajlm.
571 58. Oliveira M, Antunes W, Mota S, Madureira-Carvalho Á, Dinis-Oliveira RJ, Dias da Silva D.
572 An Overview of the Recent Advances in Antimicrobial Resistance. Microorganisms 2024,
573 Vol 12, Page 1920 [Internet]. 2024 Sep 21 [cited 2025 Mar 12];12(9):1920. Available from:
574 https://www.mdpi.com/2076-2607/12/9/1920/htm
575 59. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global
576 burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet.
577 2022 Feb 12;399(10325):629–55.
578 60. URT. The united republic of Tanzania standard treatment guidelines and national essential
579 medicines list for Tanzania mainland. 2021.
580 61. Mthombeni TC, Burger JR, Lubbe MS, Julyan M, Lekalakala-Mokaba MR, Mthombeni T.
581 African Journal of Laboratory Medicine. 2225;2225–2002. Available from:
582 https://doi.org/10.4102/ajlm.
583 62. Ampaire L, Muhindo A, Orikiriza P, Mwanga-Amumpaire J, Bebell L, Boum Y. A review of
584 antimicrobial resistance in East Africa. Vol. 5, African Journal of Laboratory Medicine.
585 AOSIS OpenJournals Publishing AOSIS (Pty) Ltd; 2016.
586 63. Mlugu EM, Mohamedi JA, Sangeda RZ, Mwambete KD. Prevalence of urinary tract
587 infection and antimicrobial resistance patterns of uropathogens with biofilm forming
588 capacity among outpatients in morogoro, Tanzania: a cross-sectional study. BMC Infect
589 Dis. 2023;23(1).
590 64. Masoud SS, Kovacevich A, Gangji R, Nyawale H, Nyange M, Ntukula A. Extent and
591 Resistance Patterns of ESKAPE Pathogens Isolated in Pus Swabs from Hospitalized
592 Patients. Canadian Journal of Infectious Diseases and Medical Microbiology. 2022;2022.
593 65. Augustine FF, Mgaya XM, Yahya SA, Niccodem EM, Matee MI. An alarming prevalence of
594 multidrug-resistant (MDR) ESKAPE pathogens and other drug-resistant bacteria isolated
595 from patients with bloodstream infections hospitalized at Muhimbili National Hospital in
596 Dar es Salaam, Tanzania. German Journal of Microbiology. 2023 Dec;3(3):7–15.
597 66. Muro RP, Masoza TS, Kasanga G, Kayange N, Kidenya BR. Predictors and outcome of first
598 line treatment failure among under-five children with community acquired severe
599 pneumonia at Bugando Medical Centre, Mwanza, Tanzania: A prospective cohort study.
600 Vol. 15, PLoS ONE. Public Library of Science; 2020.

67. Ayobami O, Brinkwirth S, Eckmanns T, Markwart R. Antibiotic resistance in hospital-acquired ESKAPE-E infections in low- and lower-middle-income countries: a systematic review and meta-analysis. Emerg Microbes Infect. 2022;11(1):443–51.
68. Mthombeni TC, Burger JR, Lubbe MS, Julyan M, Lekalakala-Mokaba MR. ESKAPE pathogen incidence and antibiotic resistance in patients with bloodstream infections at a referral hospital in Limpopo, South Africa, 2014–2019: A cross-sectional study. Afr J Lab Med [Internet]. 2024 [cited 2025 Mar 14];13(1):2519. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11621878/
69. Awuor SO, Omwenga EO, Mariita RM, Musyoki S, Musila J. Monitoring the battleground: Antimicrobial resistance, antibiofilm patterns, and virulence factors of wound bacterial isolates from patients in hospital system. [Internet]. 2023. Available from: https://www.microbiologyresearch.org/content/journal/acmi/10.1099/acmi.0.000613.v1
70. Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, González IJ, et al. Antimicrobial resistance in Africa: A systematic review. BMC Infect Dis. 2017;17(1).
71. Morris FC, Dexter C, Kostoulias X, Uddin MI, Peleg AY. The Mechanisms of Disease Caused by Acinetobacter baumannii. Front Microbiol. 2019;10(JULY).
72. Brown PD. Ciprofloxacin for the management of urinary tract infection. Womens Health (Lond) [Internet]. 2006 Jul [cited 2025 Mar 14];2(4):509–16. Available from: https://pubmed.ncbi.nlm.nih.gov/19803958/
73. Thai T, Salisbury BH, Zito PM. Ciprofloxacin. StatPearls Publishing [Internet]. 2023 Aug 28 [cited 2025 Mar 14];(2023 Jan-). Available from: https://www.ncbi.nlm.nih.gov/books/NBK535454/
74. URT. THE UNITED REPUBLIC OF TANZANIA STANDARD TREATMENT GUIDELINES AND NATIONAL ESSENTIAL MEDICINES LIST FOR TANZANIA MAINLAND. 2021 [cited 2025 Mar 7]; Available from: https://www.moh.go.tz/storage/app/uploads/public/663/c8f/ceb/663c8fceb418d132695047.pdf
75. URT. The National Action Plan on Antimicrobial Resistance 2023-2028. 2023.
76. Ramsamy Y, Essack SY, Sartorius B, Patel M, Mlisana KP. Antibiotic resistance trends of ESKAPE pathogens in Kwazulu-Natal, South Africa: A five-year retrospective analysis. Afr J Lab Med [Internet]. 2018 [cited 2025 Mar 14];7(2):887. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6295964/
77. Namubiru S, Migisha R, Okello PE, Simbwa B, Kabami Z, Agaba B, et al. Increasing trends of antibiotic resistance in Uganda: analysis of the national antimicrobial resistance surveillance data, 2018–2021. BMC Infect Dis [Internet]. 2024 Dec 1 [cited 2025 Mar 14];24(1):1–8. Available from: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-024-09806-y
78. Kitaba AA, Bonger ZT, Beyene D, Ayenew Z, Tsige E, Kefale TA, et al. Antimicrobial resistance trends in clinical Escherichia coli and Klebsiella pneumoniae in Ethiopia. Afr J Lab Med [Internet]. 2024 [cited 2025 Mar 14];13(1):2268. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11019082/
79. Greatorex B, Oosthuizen G. Organisms cultured and resistance patterns seen in a secondary referral centre ICU and burns unit. Southern African Journal of Critical Care (Online) [Internet]. 2015 [cited 2025 Mar 14];31(1):12–5. Available from:

http://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S1562-82642015000100005&lng=en&nrm=iso&tlng=en

80. Raeispour M, Ranjbar R. Antibiotic resistance, virulence factors and genotyping of Uropathogenic Escherichia coli strains. Antimicrob Resist Infect Control [Internet]. 2018 Oct 3 [cited 2025 Mar 14];7(1):1–9. Available from: https://aricjournal.biomedcentral.com/articles/10.1186/s13756-018-0411-4

81. Grossman TH. Tetracycline Antibiotics and Resistance. Cold Spring Harb Perspect Med [Internet]. 2016 Apr 1 [cited 2025 Mar 14];6(4):a025387. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4817740/

82. Handa VL, Patel BN, Bhattacharya DA, Kothari RK, Kavathia DG, Vyas BRM. A study of antibiotic resistance pattern of clinical bacterial pathogens isolated from patients in a tertiary care hospital. Front Microbiol [Internet]. 2024 [cited 2025 Mar 14];15:1383989. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11061477/

83. Beig M, Aghamohammad S, Majidzadeh N, Asforooshani MK, Rezaie N, Abed S, et al. Antibiotic resistance rates in hypervirulent Klebsiella pneumoniae strains: A systematic review and meta-analysis. J Glob Antimicrob Resist. 2024 Sep 1;38:376–88.

Supporting information

S1 Table. Quality Assessment Table

S1 Fig. Ampicillin resistance patterns among various pathogens

S2 Fig. Erythromycin resistance patterns among various pathogens

S3 Fig. Ciprofloxacin resistance patterns among various pathogens

S4 Fig. Amikacin resistance patterns among various pathogens

S5 Fig. Tetracycline resistance patterns among various pathogens

S6 Fig. Trimethoprim-sulphamethoxazole resistance patterns among various pathogens

S7 Fig. Cefotaxime resistance patterns among various pathogens

S8 Fig. Ceftazidime resistance patterns among various pathogens

S9 Fig. Cefepime resistance patterns among various pathogens

S10 Fig. Cefuroxime resistance patterns with E.coli

S11 Fig. Cefoxitin resistance patterns among various pathogens

S12 Fig. Imipenem resistance patterns among various pathogens

S13 Fig. Clindamycin resistance patterns among various pathogens

S14 Fig. Nitrofurantoin resistance patterns among various pathogens

S1 Fig A1. PRISMA 2020 Checklist